

**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Lawrence &amp; Memorial Hospital</p> <p>2. 365 Montauk Avenue New London, CT 06320-4769</p>	<p>In accordance with letter dated April 19, 2018.</p>	<p>4. Expiration Date: June 30, 2024</p>
	<p>3. License number: 06-09261-01 is amended in its entirety to read as follows:</p>	<p>5. Docket No.: 030-01275 Reference No.:</p>

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200.
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 500 millicuries total	C. For any use permitted by 10 CFR 35.300, for which the patient can be released under the provisions of 10 CFR 35.75.
D. Any byproduct material permitted by 10 CFR 35.500	D. Sealed Sources (AEA Technology, Model GD.LIN2; Isotope Products Laboratories, Model NES-8426, or A-3410)	D. 120 millicuries per source and 300 millicuries total	D. For diagnostic medical use of sealed sources permitted by 10 CFR 35.500 in compatible devices registered in accordance with 10 CFR 30.32(g).

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number

06-09261-01

Docket or Reference Number

030-01275

Amendment No. 96

**CONDITIONS**

10. A. Licensed material may be used or stored only at the licensee's facilities located at 365 Montauk Avenue, New London, Connecticut.
- B. Licensed material in Item 6.B. may be used or stored only at the licensee's facilities located at 196 Parkway South, Suite 102, Waterford, Connecticut.
11. The Radiation Safety Officer (RSO) for this license is John Sorrentino, M.D.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User(M.D.,D.O.,etc.)

Material and Use

Charles W. Andrias, M.D.

10 CFR 35.100,10 CFR 35.200,10 CFR 35.500

Roshanak Bagheri, M.D.

10 CFR 35.200

Arun Basu, M.D.

10 CFR 35.100,10 CFR 35.200; Oral administration of sodium iodide I-131; Parenteral administration of any beta emitter, or photon-emitting radionuclide with a photon energy less than 150 keV for which a written directive is required

Todd Blue, M.D.

10 CFR 35.100,10 CFR 35.200,10 CFR 35.300,10 CFR 35.500

David Brill, M.D.

10 CFR 35.200

Herman Coleman, M.D.

10 CFR 35.100,10 CFR 35.200

Jon Gaudio, M.D.

10 CFR 35.200,10 CFR 35.500

Preston R. Lamberton, M.D.

10 CFR 35.300

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number

06-09261-01

Docket or Reference Number

030-01275

Amendment No. 96

Authorized User(M.D.,D.O.,etc.)Material and Use

Thomas J. Manning, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 except oral administration of greater than 33 millicuries of sodium iodide I-131, 10 CFR 35.500

Francis J. Mirecki, M.D.

10 CFR 35.200,10 CFR 35.500

Valerie Popkin, M.D.

10 CFR 35.200,10 CFR 35.500

Pradnya Prakash-Velankar, M.D.

10 CFR 35.200

Sheldon Robbins, M.D.

10 CFR 35.100, 10 CFR 35.200, Oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries, 10 CFR 35.500

Ira Sitko, M.D.

10 CFR 35.100,10 CFR 35.200,10 CFR 35.500

Mark J. Somers, M.D.

10 CFR 35.200,10 CFR 35.500

John Sorrentino, M.D.

10 CFR 35.100,10 CFR 35.200; Oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**License Number  
06-09261-01Docket or Reference Number  
030-01275

Amendment No. 96

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated January 17, 2014 [ML14041A300]
- B. Letter dated April 21, 2014 [ML14126A387]
- C. Letter dated May 22, 2014 [ML14160A550]

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

By: Janice Nguyen  
Region 1Date: May 17, 2018